Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 4/20 | 0.40 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 4/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509760 | 0.91 | ATR (0.42) | ATRCNR2DYRK1APLK1STING1 | |
| SCHEMBL6511027 | 0.91 | ATR (0.42) | ATRCNR2DYRK1APLK1BRD4 | |
| SCHEMBL6512647 | 0.91 | CNR2 (0.45) | ATRCNR2DYRK1APLK1STING1 | |
| SCHEMBL6511907 | 0.91 | ATR (0.42) | ATRCNR2DYRK1APLK1STING1 | |
| SCHEMBL6521803 | 0.91 | PLK1 (0.44) | ATRCNR2DYRK1APLK1BRD4 | |
| SCHEMBL6511320 | 0.89 | ATR (0.42) | ATRCNR2DYRK1APLK1 | |
| SCHEMBL6518827 | 0.89 | ATR (0.41) | ATRCNR2DYRK1APLK1STING1 | |
| SCHEMBL6513798 | 0.89 | CNR2 (0.42) | ATRCNR2DYRK1APLK1STING1 | |
| SCHEMBL6512999 | 0.89 | ATR (0.42) | ATRCNR2DYRK1APLK1STING1 | |
| SCHEMBL6518580 | 0.89 | ATR (0.40) | ATRCNR2DYRK1APLK1STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | ATR 717/4885CNR2 3139/4885CAMK2D 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.